MSB 7.69% $1.19 mesoblast limited

Seeking Alpha hatchet job, page-218

  1. 15,454 Posts.
    lightbulb Created with Sketch. 5535
    Without a partnership, what are people's thoughts on the need for a cap raise?

    It is funny to see comments like these .....

    .... apart from the fact you seem to be forgetting that we have a few partnerships already (Tasly, Grünenthal, Novartis) it amazes me that posters like yourself (naysayers) don't believe that the strong phase 3 CHF results will attract a partnership deal ?

    You don't think that negotiations to a point have been happening for the last 12-18 months in relation to the CHF phase 3 trial based on a 'what if the results show x or y or z' basis ?

    May I remind you all of the details of the CHF partnership deal over a decade ago prior to the 5+ year phase 3 positive trial results we are now seeing .... don't kid yourselves - a CHF partnership deal will come with a 9 digit upfront payment and possibly even mimic the equity investment of the previous deal ten years ago of 19.99% by the chosen pharma group - just sayin' (IMO of course)

    https://www.genengnews.com/topics/t...-commercialize-mesoblast-stem-cell-therapies/

    Cephalon Shells Out $350M to Commercialize Mesoblast Stem Cell Therapies


    Cephalon is paying Mesoblast $130 million up front and will make a $220 million equity investment in the Australian firm as part of a collaboration to develop and commercialize adult mesenchymal precursor stem cell (MPC) therapies based on Mesoblast’s adult stem cell technology platform.
    Last edited by col69: 27/01/21
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.19
Change
0.085(7.69%)
Mkt cap ! $1.358B
Open High Low Value Volume
$1.10 $1.20 $1.09 $13.21M 11.37M

Buyers (Bids)

No. Vol. Price($)
1 15000 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.19 75212 5
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.